The present invention is directed to compounds that are inhibitors of
cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are
therefore useful in treating diseases mediated by these proteases. The
present invention is directed to pharmaceutical compositions comprising
these compounds and processes for preparing them.
